We aimed to further investigate the potential of VCX/Y as new targets for immunotherapy, focusing mainly on VCX2, by investigating VCX2 expression in normal and cancer tissues and examining the inducibility of VCX2 by epigenetic treatment. Here, VCX is linked to cancer.